Experimental virus therapy takes on deadly brain tumors

NCT ID NCT07472790

First seen Jun 26, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This early-stage trial tests a new treatment for recurrent high-grade glioma, an aggressive brain cancer. The approach uses a specially designed virus injected directly into the tumor to kill cancer cells and boost the immune system, combined with a PD-1 inhibitor drug that helps the immune system attack the cancer. The study will enroll 15 adults whose cancer has returned after standard treatment, to see if the combination is safe and how long they live.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
oncolytic virus Ad-TD-nsIL12 combined with a PD-1 inhibitor
What this could lead to
If successful, this could point toward a new treatment option for recurrent high-grade glioma, a brain cancer with few effective therapies.
What could go wrong
This is a very early Phase 1 trial with only 15 people, so it is too soon to know if the combination works or is safe. The virus and immune drug may cause serious side effects, and the cancer may still progress.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sanbo Brain Hospital, Capital Medical University

    Beijing, Chaoyang District, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.